Table 1 Study population
Parameters | Me (IQR), n = 37 |
|---|---|
Females, n (%) | 21/37 (56.8) |
Age of the start TCZ, years | 10.2 (6.0-12.8) |
TCZ delay, months | 36.0 (10.7-97.0) |
SoJIA related symptoms at the start of TCZ, n (%) | |
- fever | 28 (75.7) |
- rash | 24 (73.0) |
- hepatomegaly | 20 (54.1) |
- lymphadenopathy | 13 (35.1) |
- splenomegaly | 11 (29.7) |
- heart involvement | 10 (27.0) |
- interstitial lung disease | 6 (16.2) |
- CNS dysfunction | 6 (16.2) |
- coagulopathy with hemorrhage | 4 (10.8) |
Hemoglobin, g/dl | 11.0 (10.3 – 12.1) |
WBC, *109/l | 11.9 (7.9 – 16.1) |
Granulocytes, cells in 1 μl | 7812.0 (5530.0 – 13202.0) |
CRP, mg/l | 35.0 (11.6 – 88.5) |
ESR, mm/h | 42.0 (22.0 – 54.0) |
Platelets *109/l | 361.0 (299.0 – 465.0) |
Ferritin, mg/ml | 197.0 (84.0 – 841.0) |
LDH, U/l | 513.0 (425.0 – 743.0) |
Albumin, g/dl | 3.0 (2.5 – 3.2) |
Number of active joints at the start of TCZ | 7.0 (2.0 – 22.0) |
no active joints, n (%) | 4 (10.8) |
< 5 active joints, n (%) | 13 (35.1) |
≥5 active joints, n (%) | 20 (54.1) |
Treatment before TCZ administration: | |
- Corticosteroids, n (%) | 26 (70.3) |
- mean dose, mg/kg | 0,73 |
- Methotrexate, n (%) | 32 (86.5) |
- mean dose, mg/m2/week | 14,7 |
- Cyclosporine A, n (%) | 20 (54.1) |
- mean dose, mg/kg | 4,2 |
Combination | 18 (48.7) |
MAS before TCZ administration, n (%) | 12 (32.4) |